What are CYP17A1 inhibitor drugs?

CYP17A1 inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting CYP17A1 (17α-hydroxylase/17,20-lyase)). 0 are currently marketed, with 2 more in clinical development.

CYP17A1 inhibitor

0 marketed 1 in Phase 3 1 in Phase 2

This page covers all CYP17A1 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CYP17A1 (17α-hydroxylase/17,20-lyase).

Targets

CYP17A1 (17α-hydroxylase/17,20-lyase)

Phase 3 pipeline (1)

Abiraterone Acetate (AA) · Janssen Research & Development, LLC · Oncology
Abiraterone acetate inhibits CYP17A1, a key enzyme in androgen synthesis, thereby reducing testosterone production in patients with castration-resistant prostate cancer.

Phase 2 pipeline (1)

Abiraterone acetate escalated dose · Assistance Publique - Hôpitaux de Paris · Oncology
Abiraterone acetate is a CYP17A1 inhibitor that blocks androgen synthesis, reducing testosterone production to treat androgen-dependent cancers.